In contrast, monoclonal antibody therapies generally cause milder infusion reactions; for instance, daratumumab (anti-CD38) induces CRS-like symptoms in approximately 46% of patients, mostly Grade 1–2, with severe reactions occurring in about 3% [17]. This evidence concerns the gene CD38 and congenital rubella syndrome.